In a recent study published in Nature Communications, researchers establish AnimalGAN as a reliable alternative for generating synthetic pathology data in an effort to ultimately reduce animal testing ...

Waiting 72 hours to receive COVID-19 test results can feel like forever. To speed up that process for urgent, priority patients, eHealth NSW has partnered with Microsoft to use cloud technology and ...

Anyone who has endured a COVID-19 test and then counted down the hours until the results arrived knows how important it is to the patient to shrink the wait, and reduce anxiety and time in ...

On-site pathology tests for infectious diseases in rural and remote locations can be just as reliable and accurate as tests carried out in a hospital laboratory, a new report shows. On-site pathology ...

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and ...

BRISBANE, Australia: Integrated drone logistics networks will soon be shuttling pathology samples from the Moreton Bay islands to Mater Pathology testing labs under a new partnership between Mater and ...

NORTHFIELD, Ill., June 24, 2019 /PRNewswire/ -- This week, the College of American Pathologists (CAP) released a list of its longest accredited laboratories in the United States. These 41 laboratories ...

Proposed acquisition will add new anatomic pathology services, proprietary PCR tests and a national client base EL MONTE, Calif., December 22, 2025--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: ...

MOBILE, Ala.--(BUSINESS WIRE)--Synergy Laboratories (Synergy) announced today that it has acquired Mobile, Alabama-based Pathology Laboratory Associates (PLA) for an undisclosed price. The combination ...

Fulgent Genetics, Inc. FLGT recently entered into an agreement to acquire selected assets of Bako Diagnostics and to acquire StrataDx — two well-known pathology testing companies — in a combined ...

Fulgent Genetics agrees to buy StrataDx and assets from Bako Diagnostics for $55.5 million. Learn how this cash deal expands their pathology capabilities.